Franck Morschhauser

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Won Seog Kim, Tae Min Kim, Seok‐Goo Cho et al. · Nature Cancer · 2025 · 44 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study

Jehan Dupuis, Emmanuel Bachy, Franck Morschhauser et al. · The Lancet Haematology · 2024 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial

Laurence Brugières, Nathalie Cozic, Roch Houot et al. · European Journal of Cancer · 2023 · 27 citations · Full text

Medicine, Oncology, Pharmacology +16

CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, Carmelo Carlo‐Stella, Giuseppe Gritti et al. · Blood · 2022 · 23 citations

Pharmacy, Immunology, Oncology +16

Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study

Jehan Dupuis, Kunihiro Tsukasaki, Emmanuel Bachy et al. · Blood · 2022 · 23 citations

Medicine, Oncology, Pharmacotherapy +11